Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of June 30, 2026

Mon, 06 Jul 2026 11:45:00 -0400

Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News:

Median Technologies (Paris:ALMDT):

Total number of shares

49,010,638

Number of real voting rights* (excluding treasury shares**)

48,949,538

Theoretical number of voting rights*

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of June 30, 2026

Mon, 06 Jul 2026 11:45:00 -0400

Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News:

Median Technologies (Paris:ALMDT):

Total number of shares

49,010,638

Number of real voting rights* (excluding treasury shares**)

48,949,538

Theoretical number of voting rights*

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of June 30, 2026

Mon, 06 Jul 2026 11:45:00 -0400

Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News:

Median Technologies (Paris:ALMDT):

Total number of shares

49,010,638

Number of real voting rights* (excluding treasury shares**)

48,949,538

Theoretical number of voting rights*

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of June 30, 2026

Mon, 06 Jul 2026 11:45:00 -0400

Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News:

Median Technologies (Paris:ALMDT):

Total number of shares

49,010,638

Number of real voting rights* (excluding treasury shares**)

48,949,538

Theoretical number of voting rights*

Median Technologies’ eyonis® LCS Obtains CE Marking

Fri, 03 Jul 2026 01:00:00 -0400

European marketing authorization follows U.S. FDA clearance of eyonis® LCS, Median’s AI-based Software as a Medical Device designed to aid in the detection and diagnosis of lung cancer in screening programs
CE marking enables the commercial launch of eyonis® LCS across the European Union
eyonis® LCS’ unique technology and performance will empower lung cancer screening programs to enable earlier diagnosis, as screening initiatives continue to expand across Europe

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News:

Median Technologies (FR0011049824, ALMDT, “Median” or the “Company”), manufacturer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early

Median Technologies’ eyonis® LCS Obtains CE Marking

Fri, 03 Jul 2026 01:00:00 -0400

European marketing authorization follows U.S. FDA clearance of eyonis® LCS, Median’s AI-based Software as a Medical Device designed to aid in the detection and diagnosis of lung cancer in screening programs
CE marking enables the commercial launch of eyonis® LCS across the European Union
eyonis® LCS’ unique technology and performance will empower lung cancer screening programs to enable earlier diagnosis, as screening initiatives continue to expand across Europe

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News:

Median Technologies’ eyonis® LCS Obtains CE Marking

Fri, 03 Jul 2026 01:00:00 -0400

European marketing authorization follows U.S. FDA clearance of eyonis® LCS, Median’s AI-based Software as a Medical Device designed to aid in the detection and diagnosis of lung cancer in screening programs
CE marking enables the commercial launch of eyonis® LCS across the European Union
eyonis® LCS’ unique technology and performance will empower lung cancer screening programs to enable earlier diagnosis, as screening initiatives continue to expand across Europe

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News:

Median Technologies’ eyonis® LCS Obtains CE Marking

Fri, 03 Jul 2026 01:00:00 -0400

European marketing authorization follows U.S. FDA clearance of eyonis® LCS, Median’s AI-based Software as a Medical Device designed to aid in the detection and diagnosis of lung cancer in screening programs
CE marking enables the commercial launch of eyonis® LCS across the European Union
eyonis® LCS’ unique technology and performance will empower lung cancer screening programs to enable earlier diagnosis, as screening initiatives continue to expand across Europe

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News:

Median Technologies’ eyonis® LCS Obtains CE Marking

Fri, 03 Jul 2026 01:00:00 -0400

European marketing authorization follows U.S. FDA clearance of eyonis® LCS, Median’s AI-based Software as a Medical Device designed to aid in the detection and diagnosis of lung cancer in screening programs
CE marking enables the commercial launch of eyonis® LCS across the European Union
eyonis® LCS’ unique technology and performance will empower lung cancer screening programs to enable earlier diagnosis, as screening initiatives continue to expand across Europe

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News:

Median Technologies’ eyonis® LCS Obtains CE Marking

Fri, 03 Jul 2026 01:00:00 -0400

European marketing authorization follows U.S. FDA clearance of eyonis® LCS, Median’s AI-based Software as a Medical Device designed to aid in the detection and diagnosis of lung cancer in screening programs
CE marking enables the commercial launch of eyonis® LCS across the European Union
eyonis® LCS’ unique technology and performance will empower lung cancer screening programs to enable earlier diagnosis, as screening initiatives continue to expand across Europe

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News:

Median Technologies’ eyonis® LCS Obtains CE Marking

Fri, 03 Jul 2026 01:00:00 -0400

European marketing authorization follows U.S. FDA clearance of eyonis® LCS, Median’s AI-based Software as a Medical Device designed to aid in the detection and diagnosis of lung cancer in screening programs
CE marking enables the commercial launch of eyonis® LCS across the European Union
eyonis® LCS’ unique technology and performance will empower lung cancer screening programs to enable earlier diagnosis, as screening initiatives continue to expand across Europe

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News:

Median Technologies’ eyonis® LCS Obtains CE Marking

Fri, 03 Jul 2026 01:00:00 -0400

European marketing authorization follows U.S. FDA clearance of eyonis® LCS, Median’s AI-based Software as a Medical Device designed to aid in the detection and diagnosis of lung cancer in screening programs
CE marking enables the commercial launch of eyonis® LCS across the European Union
eyonis® LCS’ unique technology and performance will empower lung cancer screening programs to enable earlier diagnosis, as screening initiatives continue to expand across Europe

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News:

Median Technologies’ eyonis® LCS Obtains CE Marking

Fri, 03 Jul 2026 01:00:00 -0400

European marketing authorization follows U.S. FDA clearance of eyonis® LCS, Median’s AI-based Software as a Medical Device designed to aid in the detection and diagnosis of lung cancer in screening programs
CE marking enables the commercial launch of eyonis® LCS across the European Union
eyonis® LCS’ unique technology and performance will empower lung cancer screening programs to enable earlier diagnosis, as screening initiatives continue to expand across Europe

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News:

Median Technologies’ eyonis® LCS Obtains CE Marking

Fri, 03 Jul 2026 01:00:00 -0400

European marketing authorization follows U.S. FDA clearance of eyonis® LCS, Median’s AI-based Software as a Medical Device designed to aid in the detection and diagnosis of lung cancer in screening programs
CE marking enables the commercial launch of eyonis® LCS across the European Union
eyonis® LCS’ unique technology and performance will empower lung cancer screening programs to enable earlier diagnosis, as screening initiatives continue to expand across Europe

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News:

Median Technologies’ eyonis® LCS Obtains CE Marking

Fri, 03 Jul 2026 01:00:00 -0400

European marketing authorization follows U.S. FDA clearance of eyonis® LCS, Median’s AI-based Software as a Medical Device designed to aid in the detection and diagnosis of lung cancer in screening programs
CE marking enables the commercial launch of eyonis® LCS across the European Union
eyonis® LCS’ unique technology and performance will empower lung cancer screening programs to enable earlier diagnosis, as screening initiatives continue to expand across Europe

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News:

Median Technologies’ eyonis® LCS Obtains CE Marking

Fri, 03 Jul 2026 01:00:00 -0400

European marketing authorization follows U.S. FDA clearance of eyonis® LCS, Median’s AI-based Software as a Medical Device designed to aid in the detection and diagnosis of lung cancer in screening programs
CE marking enables the commercial launch of eyonis® LCS across the European Union
eyonis® LCS’ unique technology and performance will empower lung cancer screening programs to enable earlier diagnosis, as screening initiatives continue to expand across Europe

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News:

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of May 31, 2026

Mon, 08 Jun 2026 11:45:00 -0400

Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News:

Median Technologies (Paris:ALMDT):

Total number of shares

38,202,387

Number of real voting rights* (excluding treasury shares**)

38,143,292

Theoretical number of voting rights*

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of May 31, 2026

Mon, 08 Jun 2026 11:45:00 -0400

Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News:

Median Technologies (Paris:ALMDT):

Total number of shares

38,202,387

Number of real voting rights* (excluding treasury shares**)

38,143,292

Theoretical number of voting rights*

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of May 31, 2026

Mon, 08 Jun 2026 11:45:00 -0400

Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News:

Median Technologies (Paris:ALMDT):

Total number of shares

38,202,387

Number of real voting rights* (excluding treasury shares**)

38,143,292

Theoretical number of voting rights*

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of May 31, 2026

Mon, 08 Jun 2026 11:45:00 -0400

Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News:

Median Technologies (Paris:ALMDT):

Total number of shares

38,202,387

Number of real voting rights* (excluding treasury shares**)

38,143,292

Theoretical number of voting rights*

Median Technologies Launches a Capital Increase of €40 million, with Potential Upsize to €50 million, to Support the Deployment of eyonis® LCS in the U.S. and Europe and Advance New Clinical Indi

Wed, 27 May 2026 01:00:00 -0400

Share capital increase without shareholders’ preferential subscription rights, to be carried out by way of an issue of ordinary shares in the framework of a public offering, for an amount of approximately 40 million euros.
A share capital increase without shareholders’ preferential subscription rights reserved for the Guarantors (as defined below) for a maximum amount of 10 million euros, should all the ordinary shares issued in the framework of the public offering be fully subscribed;
Firm subscription and backstop commitments for a total amount of 30 million euros, including 20 million euros under the subscription commitments, representing total commitments equal to

Median Technologies Launches a Capital Increase of €40 million, with Potential Upsize to €50 million, to Support the Deployment of eyonis® LCS in the U.S. and Europe and Advance New Clinical Indi

Wed, 27 May 2026 01:00:00 -0400

Share capital increase without shareholders’ preferential subscription rights, to be carried out by way of an issue of ordinary shares in the framework of a public offering, for an amount of approximately 40 million euros.
A share capital increase without shareholders’ preferential subscription rights reserved for the Guarantors (as defined below) for a maximum amount of 10 million euros, should all the ordinary shares issued in the framework of the public offering be fully subscribed;
Firm subscription and backstop commitments for a total amount of 30 million euros, including 20 million euros under the subscription commitments, representing total commitments equal to

Median Technologies Launches a Capital Increase of €40 million, with Potential Upsize to €50 million, to Support the Deployment of eyonis® LCS in the U.S. and Europe and Advance New Clinical Indi

Wed, 27 May 2026 01:00:00 -0400

Share capital increase without shareholders’ preferential subscription rights, to be carried out by way of an issue of ordinary shares in the framework of a public offering, for an amount of approximately 40 million euros.
A share capital increase without shareholders’ preferential subscription rights reserved for the Guarantors (as defined below) for a maximum amount of 10 million euros, should all the ordinary shares issued in the framework of the public offering be fully subscribed;
Firm subscription and backstop commitments for a total amount of 30 million euros, including 20 million euros under the subscription commitments, representing total commitments equal to

Median Technologies Launches a Capital Increase of €40 million, with Potential Upsize to €50 million, to Support the Deployment of eyonis® LCS in the U.S. and Europe and Advance New Clinical Indi

Wed, 27 May 2026 01:00:00 -0400

Share capital increase without shareholders’ preferential subscription rights, to be carried out by way of an issue of ordinary shares in the framework of a public offering, for an amount of approximately 40 million euros.
A share capital increase without shareholders’ preferential subscription rights reserved for the Guarantors (as defined below) for a maximum amount of 10 million euros, should all the ordinary shares issued in the framework of the public offering be fully subscribed;
Firm subscription and backstop commitments for a total amount of 30 million euros, including 20 million euros under the subscription commitments, representing total commitments equal to

Median Technologies Launches a Capital Increase of €40 million, with Potential Upsize to €50 million, to Support the Deployment of eyonis® LCS in the U.S. and Europe and Advance New Clinical Indi

Wed, 27 May 2026 01:00:00 -0400

Share capital increase without shareholders’ preferential subscription rights, to be carried out by way of an issue of ordinary shares in the framework of a public offering, for an amount of approximately 40 million euros.
A share capital increase without shareholders’ preferential subscription rights reserved for the Guarantors (as defined below) for a maximum amount of 10 million euros, should all the ordinary shares issued in the framework of the public offering be fully subscribed;
Firm subscription and backstop commitments for a total amount of 30 million euros, including 20 million euros under the subscription commitments, representing total commitments equal to

StreetInsider.com News Articles

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of June 30, 2026

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of June 30, 2026

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of June 30, 2026

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of June 30, 2026

Median Technologies’ eyonis® LCS Obtains CE Marking

Median Technologies’ eyonis® LCS Obtains CE Marking

Median Technologies’ eyonis® LCS Obtains CE Marking

Median Technologies’ eyonis® LCS Obtains CE Marking

Median Technologies’ eyonis® LCS Obtains CE Marking

Median Technologies’ eyonis® LCS Obtains CE Marking

Median Technologies’ eyonis® LCS Obtains CE Marking

Median Technologies’ eyonis® LCS Obtains CE Marking

Median Technologies’ eyonis® LCS Obtains CE Marking

Median Technologies’ eyonis® LCS Obtains CE Marking

Median Technologies’ eyonis® LCS Obtains CE Marking

Median Technologies’ eyonis® LCS Obtains CE Marking

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of May 31, 2026

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of May 31, 2026

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of May 31, 2026

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of May 31, 2026

Median Technologies Launches a Capital Increase of €40 million, with Potential Upsize to €50 million, to Support the Deployment of eyonis® LCS in the U.S. and Europe and Advance New Clinical Indi

Median Technologies Launches a Capital Increase of €40 million, with Potential Upsize to €50 million, to Support the Deployment of eyonis® LCS in the U.S. and Europe and Advance New Clinical Indi

Median Technologies Launches a Capital Increase of €40 million, with Potential Upsize to €50 million, to Support the Deployment of eyonis® LCS in the U.S. and Europe and Advance New Clinical Indi

Median Technologies Launches a Capital Increase of €40 million, with Potential Upsize to €50 million, to Support the Deployment of eyonis® LCS in the U.S. and Europe and Advance New Clinical Indi

Median Technologies Launches a Capital Increase of €40 million, with Potential Upsize to €50 million, to Support the Deployment of eyonis® LCS in the U.S. and Europe and Advance New Clinical Indi